| [1] Rambaldi A, Biagi E, Bonini C, et al. Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia. 2015;29(1):1-10.[2] Weissinger EM, Borchers S, Silvani A, et al. Long term follow up of patients after allogeneic stem cell transplantation and transfusion of HSV-TKtransduced T-cells. Front Pharmacol. 2015;23(6):76:1-9.[3] Bornhauser M, Thiede C, Platzbecker U, et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T celldepleted allogeneic hematopoietic cell transplantationin patients with chronic myeloid leukemia. Blood. 2011;117(26):7174-7184.[4] Luo Y, Zeng HQ, Shen Y, et al. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: a phase I study in patients with relapsed/refractory hematologic malignancies. Leuk Res. 2016;48:6-10.[5] Krishnamurthy P, Potter VT, Barber LD, et al. Outcome of donor lymphocyte infusion after t celledepleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2013;19:562-568.[6] Bar M, Sandmaier BM, Inamoto Y, et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3 T cell dose. Biol Blood Marrow Transplant. 2013;19(6):949-957.[7] Yun HD, Waller EK. Finding the sweet spot for donor lymphocyte infusions. Biol Blood Marrow Transplant. 2013;19(4):507-508.[8] Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009;113(7): 1581-1588.[9] Huang XJ, Liu DH, Xu LP, et al. Prophylactic infusion of donor granulocyte colony stimulating factor mobilizedperipheral blood progenitor cells after allogeneic hematological stem celltransplantation in patients with high-risk leukemia. Leukemia. 2006;20:365-368.[10] Huang X, Guo N, Ren H, et al. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients allogeneic bone marrow transplantation. Chin Med. 2003;116.736-741.[11] Nishimura E, Sakihama T, Setoguchi R, et al. Induction of antigen-specific immunolugic tolerance by in vivo and in vitro antigen-specific expansin of naturally arising Foxp3+CD25+ CD4+ regulation T cell. Int Immunol. 2004;16(8): 1189-1207.[12] Rezvani K, Mielke S, Ahmadzadeh M, et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD followingHLA-matched allogeneic SCT. Blood. 2006;108(4):1291-1297.[13] Delia M, Pastore D, Mestice A, et al. Outcome of allogeneic peripheral blood stem cell transplantation by donor graft CD3+/Tregs ratio: a single-center experience. Biol Blood Marrow Transplant. 2013;19(3):495-499.[14] Pang NN, Duan XL, Jiang M, et al. Reconstitution and clinical signifcance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro. Int J Clin Exp Pathol. 2015;8(8):8892- 8901.[15] Stanzani M, Martins SL, Saliba RM, et al. CD25 expression on donor CD4+ or CD8+ T cells is associated with an increased risk for graft-versus-host disease after HLA-identical stem cell transplantation in humans. Blood. 2004;103:1140-1146.[16] Ukena SN, Grosse J, Mischak-Weissinger E, et al. Acute but not chronic graft-versus-host disease is associated with a reduction of circulating CD4+CD25highCD127low/−regulatory T cells. Blood. 2010;66:664-672.[17] Shaffer BC, Le Luduec JB, Forlenza C, et al. Phase ii study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(4):705-709.[18] Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433-440.[19] Locatelli F, Merli P, Rutella S. At the bedside:innate immunity as an immunotherapy tool for hematological malignancies. J Leukoc Biol. 2013;94(6):1141-1157.[20] Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol. 2014;192(10):4592-4600.[21] Mezger M, Bornhäuser M, Trenschel R, et al. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts. Ann Hematol. 2014;93(9):1579-1586.[22] Park S, Kim K, Jang JH, et al. KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneichematopoietic stem cell transplantation: Result of single center prospective study. Hum Immunol. 2015;76(9):636-643. [23] Choi I, Yoon SR, Park SY, et al. Donor-derived natural killer cells infused after human leukocyte antigen–haploidentical hematopoietic cell transplantation: a dose-escalation study. Biol Blood Marrow Transplant. 2014;20(5):696-704. [24] Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.[25] Bishara A, De Santis D, Witt CC, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens. 2004;63:204-211.[26] Huang XJ, Zhao XY, Liu DH, et al. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia. 2007;21:848-851.[27] Zhao XY, Chang YJ, Huang XJ. Conflicting impact of alloreactive nk cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences? 2011;10: 1436-1442.[28] Chang YJ, Zhao XY, Huang XJ, et al. Effects of the NK cellrecovery on outcomes of unmanipulated haploidentical blood andmarrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant. 2008;14(3):323-334.[29] Yanez R, Lamana ML, Garcia-Castro J, et al. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells. 2006;24:2582- 2591.[30] Gao L, Zhang YQ, Hu BY, et al. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord–derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after hla-haploidentical stem-cell transplantation. Clin Oncol. 2016; 20;34(24):2843-2850.[31] Selmani Z, Naji A, Zidi I, et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25high FOXP3+ regulatory T cells. Stem Cells. 2008;26: 212-222.[32] Burchell JT, Strickland DH, Stumbles PA. The role of dendritic cells and regulatory T cells in the regulation of allergic asthma. Pharmacol Ther. 2010;125:1-10.[33] Glennie S, Soeiro I, Dyson PJ, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005;105:2821-2827. [34] Asari S, Itakura S, Ferreri K, et al. Mesenchymal stem cells supress B-cell terminal differentiation. Exp Hematol. 2009;37: 604-615.[35] Kuzmina LA, Petinati NA, Parovichnikova EN, et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease-a phase ii study. Stem Cells Int. 2012;2012:968213.[36] Baron F, Lechanteur C, Willems E, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transplant. 2010;16:838-847.[37] Zhao K, Lou R, Huang F, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease afterhematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21(1):97-104.[38] Li XH, Gao CJ, Da WM, et al. Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia. PLoS One. 2014;9(3):e89666.[39] Muroi K, Miyamura K, Okada M, et al. Bone marrow-derived mesenchymal stem cells(JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J hematol. 2016;103(2):243-250.[40] Le Blanc K, Samuelesson H, Gustafasson B, et al. Transplantation of Mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukmia. 2007; 21:1733-1738.[41] Ning H, Yang F, Jiang M, et al. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia. 2008;22:593-599.[42] 杨廷,江明.减低剂量预处理方案在亲缘HLA单倍体相合造血干细胞移植中的应用[J].中国组织工程研究,2015,19(6):955-961. |
